On the association between valproate and polycystic ovary syndrome

Epilepsia

Volumn 42, Issue 3, 2001, Pages 295-304

  Genton, Pierre ^a   Bauer, Jürgen ^b   Duncan, Susan ^c   Taylor, Ann E ^d   Balen, Adam H ^e   Eberle, Andrea ^f   Pedersen, Birthe ^g   Salas Puig, Xavier ^h   Sauer, Mark V ⁱ  

^a CENTRE SAINT PAUL   (France)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c HOPE HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f ARKANSAS CHILDREN S HOSPITAL   (United States)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h Hospital de Asturias   (Spain)

ⁱ New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Epilepsy; Insulin resistance; Polycystic ovaries; Polycystic ovary syndrome; Valproate

Indexed keywords

INSULIN; LAMOTRIGINE; VALPROIC ACID;

ANTICONVULSANT THERAPY; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOGRAPHY; ENVIRONMENTAL FACTOR; EPILEPSY; EVIDENCE BASED MEDICINE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERINSULINISM; HYPOPHYSIS FUNCTION; HYPOTHALAMUS FUNCTION; INCIDENCE; INSULIN RESISTANCE; MEDICAL LITERATURE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTICONVULSANTS; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES; PREVALENCE; VALPROIC ACID;

EID: 0035061957     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.28899.x     Document Type: Review

References (102)

1. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin
2. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
3. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
4. Treatment of idiopathic (primary) generalized epilepsies
5. Monotherapy with valproate in primary generalized epilepsies
6. Divalproex treatment of mania in elderly patients
7. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura
8. Polycystic ovary syndrome: A changing perspective
9. Amenorrhoea associated with bilateral polycystic ovaries
10. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients
11. Multi-follicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin-releasing hormone
12. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
13. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients
14. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism
15. The polycystic ovary syndrome
16. Fetal growth, length of gestation, and polycystic ovaries in adult life
17. Sonographic incidence of polycystic ovaries in a gynecological population
18. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women
19. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?
20. Polycystic ovaries - A common finding in normal women
21. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
22. Familial polycystic ovaries: A genetic disease
23. Familial clustering in the polycystic ovarian syndrome
24. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness
25. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
26. The genetic basis of polycystic ovary syndrome
27. A twin study of polycystic ovary syndrome and lipids
28. Responses of serum gonadotrophins to LH releasing hormone and oestrogens in Japanese women with polycystic ovaries
29. Does testosterone affect the normal menstrual cycle?
30. 11-Hydroxylase with affinity to C21-deoxysteroids from ovaries of patients with polycystic ovary syndrome
31. Pituitary-ovarian responses to naterelin testing in polycystic ovary syndrome
32. Insulin-like growth factors as intra-ovarian regulators of granulosa cell growth and function
33. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women
34. Insulin regulation of insulin-like growth factor binding protein-1 in obese and non-obese humans
35. Inhibition of sex hormone binding globulin production in human hepatoma (Hep G2) cell line by insulin and prolactin
36. Characterization of obese women with reduced sex-hormone binding globulin concentrations
37. Control of luteinizing hormone secretion in polycystic ovary syndrome
38. Effects of luteinizing hormone, insulin, insulin-like growth factor-1 and insulin-like growth factor small binding protein 1 in the polycystic ovary syndrome
39. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
40. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovary disease
41. Insulin resistance in nonobese patients with polycystic ovarian syndrome
42. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
43. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
44. Prevalence and predictors of risk for type 2 diabetes and impaired glucose tolerance in polycystic ovary syndrome: A prospective, controlled study in 254 affected women
45. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus
46. Polycystic ovaries in women with gestational diabetes
47. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome
48. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome
49. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
50. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome
51. Standards for ovarian volume in childhood and puberty
52. Pubertal maturation of the internal genitalia: An ultrasound evaluation of 166 healthy girls
53. Puberty and polycystic ovarian syndrome: The insulin/insulin-like growth factor I hypothesis
54. Metabolic features of polycystic ovary syndrome are found in adolescent girls
55. Marriage and fertility in epileptic patients
56. Fertility in patients with epilepsy: A population-based study
57. Fertility in persons with epilepsy: 1935-1974
58. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: Social and biologic influences
59. Reproduction among individuals with idiopathic/cryptogenic epilepsy: Risk factors for reduced fertility in marriage
60. Serum prolactin in epilepsy and hysteria
61. Epilepsy and prolactin in adults: A clinical review
62. Comparison of the effects of frontal and temporal lobe partial seizures on prolactin levels
63. Serum prolactin and cortisol concentrations after grand mal seizures
64. Prolactin and gonadotrophin changes following generalized and partial seizures
65. The hormonal responses to generalized tonic-clonic seizures
66. Effect of interictal epileptiform discharges on nocturnal plasma prolactin concentrations in epileptic patients with complex partial seizures
67. Serum prolactin concentrations and epilepsy: A study which compares healthy subjects with a group of patients in presurgical evaluation and circadian variations with those related to seizures
68. Temporal lobe epilepsy: Follow-up investigation of 74 temporal lobe resected patients
69. Temporal lobe epilepsy: An extrahypothalamic pathogenesis for polycystic ovarian syndrome?
70. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy
71. Altered pulsatile secretion of luteinizing hormone in women with epilepsy
72. Reproductive endocrine disorders in women with primary generalized epilepsy
73. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy
74. Reduced fertility and neuroendocrine dysfunction in women with epilepsy
75. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy
76. Plasma prolactin increase following electrical stimulation of the amygdala in humans
77. The effect of limbic and extralimbic stimulations upon prolactin secretion in humans
78. Effects of antiepileptic drugs on hormones
79. Sexual function in women with epilepsy
80. Serum hormones in male epileptic patients receiving anticonvulsant medication
81. Differential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients
82. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication
83. Effects of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man
84. Hormone binding globulins and anticonvulsant therapy
85. Prolactin and growth hormone dynamics in epileptic patients receiving phenytoin
86. Phenytoin-induced elevation of serum oestradiol and reproductive dysfunction in men with epilepsy
87. Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients
88. Influence of sodium valproate on medium-late luteal phase pulsatile LH secretion in normal women
89. Hypothalamic pituitary testing on children receiving CBZ or sodium valproate
90. Pubertal arrest associated with valproic acid therapy
91. Juvenile myoclonic epilepsy
92. Bulimia: Its incidence and clinical importance in patients with anorexia nervosa
93. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study
94. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy
95. Polycystic ovaries in women taking valproate monotherapy for epilepsy: A two centre study
96. Valproate-related endocrine risks in women with epilepsy: A multicenter study
97. Hyperinsulinaemia, polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy
98. Obesity and endocrine disorders in women taking valproate for epilepsy
99. Polycystic ovarian syndrome in women with epilepsy: Epileptic or iatrogenic?
100. The effects of valproate, carbamazepine, and oxcarbamazepine on growth and sexual maturation in girls with epilepsy
101. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy
102. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain